Please login to the form below

Not currently logged in
Email:
Password:

Gentium

This page shows the latest Gentium news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

Latest news

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz offers $1bn for Italy's Gentium. Will gain access to recently-approved liver drug Defitelio. ... Shares in Nasdaq-listed Gentium closed just above $55.65 the day before the deal was announced.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Gentium expects EMA rejection for defibrotide. Negative feedback for drug’ s use in liver condition associated with stem cell transplantation. ... Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics